SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.02-$0.59 (-6.85%)
 
Market cap
$41.2M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 15, 2021
Market Cap$41.17M-24.1%
Revenue (ttm)$200.00K
Net Income-$11.02M+10.8%
EPS-$2.24+26.8%
Shares Out5.13M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume19,030
Open$8.32
Previous Close$8.61
Day's Range$7.76 - $8.60
52-Week Range$7.76 - $16.93
Beta0.45
AnalystsBuy
Price Target$35.00(+336.41%)
Earnings DateMar 23, 2027
-8.13% (1D)
No price history available.

About INKT

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Address
149 Fifth Avenue, New York City, NY, 10010, US
Market Cap
41 million
Employees
15
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$119.89K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating INKT in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From INKT’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-6.85%
5 Days
-17.49%
1 Month
-24.48%
6 Months
-26.69%
1 Year
-24.05%

$INKT stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in INKT holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by INKT's directors and management

Net Shares Purchased by Insiders−7k−4k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

INKT Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New INKT patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to INKT from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in INKT

VTIVanguard Morningstar Total Stock Market ETF$440.36K
VXFVanguard Extended Market ETF$161.97K
IWCiShares Micro-Cap ETF$52.74K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from INKT’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Q3 revenue beats, first commercial product revenue, ARDS trial advancement, and ARPA-H selection demonstrate meaningful clinical and commercial progress.

Recent Insider Activity

Buys
0
Sells
9
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.